KETAMINE assisted Therapy and

Plant Medicine Harm reduction/IntegratioN

Bold embrace is now offering PHRI Psychedelic Harm Reduction and Integration. We offer legalized Ketamine Assisted Psychotherapy in an innovative collaborative care model w medical staff of Journey Clinical; as well as PHRI for individuals utilizing mushrooms, plant medicines and sacred ceremony. Recent clinical research on plant medicines and psychedelics have proven successful outcomes in increasing neuro-plasticity and neuro genesis, they can essentially “rewire” our brains. They can bring about a profound healing mind and soul, while imparting a lasting impression/ felt sense of euphoria, connection, meaning, love and purpose. MAPS Multidisciplinary Association of Psychedelic Studies (https://maps.org/) clinical trial outcomes for treating Trauma, Depression, Anxiety, and Addiction have had resoundingly positive results, even in comparison with traditional SSRI’s and stand alone therapy. Because of these scientific studies, and changing political climate around “the war on drugs”, some MA cities (Northampton, Cambridge, Somerville) recently decriminalized psilocybin personal use; Oregon leads the Nation w medical use beginning 2023. As more cities and states move toward reclassifying these substances and making their mental health benefits accessible, clinical experts anticipate official FDA recognition that these substances indeed have relatively safe and important mental health and public health applications- especially in light of the USA’S severe post-pandemic mental health crisis, the 30% increase in Suicide rates since 2020, and the ongoing Opioid epidemic.

Lori has completed the Fluence Ketamine training 2022, the Integrative Psychiatry Institute’s year long Psychedelic assisted psychotherapy program cohort 3, and has integrated her clinical expertise with extensive and reverent study of ceremony and ancient healing traditions in Quintana Roo, Mexico. She facilitates ketamine journeys for groups, individuals, and offers experiential trainings for clinicians new to this therapy.

Articles:

https://www.journalofpsychedelicpsychiatry.org/_files/ugd/e07c59_397e1817694b465699d82a3c163c1f2a.pdf?index=true

https://www.tandfonline.com/doi/full/10.1080/02791072.2019.1587556

https://pubmed.ncbi.nlm.nih.gov/35285721/

https://digitalcommons.ciis.edu/cgi/viewcontent.cgi?article=1191&context=ijts-transpersonalstudies

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753268/

https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/repeated-oral-ketamine-for-outpatient-treatment-of-resistant-depression-randomised-doubleblind-placebocontrolled-proofofconcept-study/76898B0B3980372F9EE79043F55A08FD